Novartis to acquire Japanese giant Takeda’s eye drug assets for $3.4b

FILE PHOTO: Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo, Japan, July 2, 2018. REUTERS/Kim Kyung-Hoon - RC1702FA7D40/File Photo

Novartis AG agreed to pay $3.4 billion for eye-disease medicines that Takeda Pharmaceutical Co. is selling to shed debt after its $62 billion acquisition of Shire Plc.

The main product in the deal is Xiidra, prescription drops that compete with Allergan Plc’s blockbuster Restasis to relieve dry-eye disease, a common condition that can hinder daily activities ranging from reading to driving. Along with $3.4 billion in cash upfront, Novartis agreed to pay as much as $1.9 billion in milestones.

The deal gives Chief Executive Officer Vas Narasimhan, who is working to reshape the Swiss drugmaker, a simple new medicine with blockbuster potential as he expands into less certain fields such as gene therapy. Under Narasimhan, Novartis is narrowing its focus on cutting-edge drugs for cancer and rare illnesses. In his first year at the helm, the new chief split with the eye-care division Alcon, ditched a stake in a consumer-health venture and carried out three crucial acquisitions.

Blockbuster Potential

Xiidra had about $400 million in sales last year, Novartis said. It expects the deal to close in the second half of the year and plans to bring over about 400 employees. The drug could generate peak sales of as much as $1.4 billion, according to Elizabeth Krutoholow, a Bloomberg Intelligence analyst. Bloomberg reported the potential sale earlier Wednesday.

Novartis has just spun off its Alcon contact-lens and surgical-products division but previously transferred eye drugs from the unit to the main pharma business. Xiidra’s previous owner, Shire, tangled with Allergan in the U.S. in an effort to gain greater market access for the drug.

Novartis shares fell less than 1 percent to 83 Swiss francs in Zurich trading. Takeda shares rose as much as 3.3 percent in early Tokyo trading Thursday, before giving up gains to close mostly unchanged.

The transaction is the first major deal for Takeda since Chief Executive Officer Christophe Weber said in January that the Japanese company plans to move quickly on disposals to reduce debt after its $62 billion takeover of Shire.

Takeda took on around $31 billion of debt for the Shire takeover, boosting its net debt ratio to five times earnings, compared to an industry average of one. The company has said that its medium-term debt target is around two times earnings. The company has laid out a scenario of a potential $10 billion in divestments. Besides the eye-care deal with Novartis, it agreed to sell Tachosil, a surgical patch, to Ethicon Inc. for $400 million.

Also Read: 

Japan’s Takeda invites Brazilian pharma firms to bid for Latam business

Japan’s Taisho close to acquiring Bristol-Myers OTC unit in $1.6b deal

Bloomberg

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.